| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| WB Predicted band size | 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human TAT |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TAT抗体的3篇示例文献摘要，涵盖不同研究方向(注：文献为虚构示例，仅供参考)：
---
1. **"Neutralizing Efficacy of Tetanus Antitoxin (TAT) Antibodies in Emergency Prophylaxis"**
*作者：Smith A, et al.*
摘要：研究评估了破伤风抗毒素(TAT)抗体的中和能力，发现其在动物模型中能有效阻断破伤风毒素的神经毒性，强调了抗体纯度与给药时机对临床预后的重要性。
2. **"Autoantibodies Against Tyrosine Aminotransferase in Metabolic Liver Diseases"**
*作者：Lee J, et al.*
摘要：首次报道酪氨酸氨基转移酶(TAT)自身抗体在非酒精性脂肪性肝炎患者血清中的异常表达，提示其可能作为肝损伤的新型生物标志物。
3. **"Development of a TAT Antibody-Based ELISA for Rapid Toxin Detection"**
*作者：Zhang Y, et al.*
摘要：利用重组TAT抗体建立高灵敏度ELISA检测方法，可快速识别破伤风毒素，适用于低资源地区急诊筛查，检测限达0.1 ng/mL。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词如“Tetanus Antitoxin Antibody”或“Tyrosine Aminotransferase Autoantibody”。
**Background of TAT Antibody**
TAT (Tetanus Antitoxin) antibodies are immunoglobulins developed to neutralize the potent neurotoxin produced by *Clostridium tetani*, the bacterium responsible for tetanus. This toxin, tetanospasmin, disrupts neurotransmitter release, causing severe muscle spasms and potentially fatal respiratory failure. TAT antibodies function by binding to the toxin, preventing its interaction with neuronal receptors.
Historically, TAT antibodies were derived from hyperimmunized animals (e.g., horses), providing passive immunity in post-exposure prophylaxis or treatment. Developed in the early 20th century, such antitoxins significantly reduced tetanus mortality. However, heterologous (animal-derived) antibodies carry risks of hypersensitivity reactions, including serum sickness. Modern approaches prioritize human tetanus immunoglobulin (HTIG), which offers longer protection and reduced immunogenicity.
Tetanus remains a concern in regions with limited vaccination access. TAT antibodies, though less commonly used today, represent a critical milestone in immunology, highlighting the transition from animal-based therapies to safer, human-derived biologics. Current prevention relies on active immunization with tetanus toxoid vaccines, but passive antibody administration retains value in unvaccinated individuals or emergency settings. Research continues to optimize antibody formulations for broader accessibility and safety.
×
